CHU de Lille
Lille, 59037, France
Location status: Recruiting
NCT Number: NCT04621357
In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Lille, 59037, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Brain MRI will include differents sequences.
Biological biomarkers will include a set of systemic inflammatory markers
Time frame: at 3 months
Time frame: at 3 months and 12 months
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.
The scale runs from 0-6, running from perfect health without symptoms to death.
Time frame: at 96 hours
The NIHSS score (NIH Stroke Scale) is used to monitor the progression of an ischemic or hemorrhagic stroke. It is rated from 0 to 42 points. Depending on the result, a distinction is made from Minor stroke to Severe stroke
Time frame: at 3 and 12 months
Time frame: at 3 months, at 12 months
Cognitive decline defined as a score on MOCA test below 27
Contact information is provided by the study sponsor or research team.
University Hospital, Lille
Other
Consequences of Oedema on the Prognosis of InTraCerebral Haemorrhage
Acronym: COPITCH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04434807
Brain Diseases, Cardiovascular Diseases
Newcastle, New South Wales, Australia
View Trial DetailsNCT05611918
Behavior, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06402968
Brain Diseases, Cardiovascular Diseases
Irvine, California, United States
View Trial DetailsNCT06352632
Brain Diseases, Cardiovascular Diseases
Sydney, New South Wales, Australia
View Trial Details